161 related articles for article (PubMed ID: 35617682)
21. Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
Nikiforow S; Kim HT; Bindra B; McDonough S; Glotzbecker B; Armand P; Koreth J; Ho VT; Alyea EP; Blazar BR; Ritz J; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2013 May; 19(5):804-11. PubMed ID: 23416855
[TBL] [Abstract][Full Text] [Related]
22. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
[TBL] [Abstract][Full Text] [Related]
23. Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease.
Asano T; Matsuoka KI; Iyama S; Ohashi K; Inamoto Y; Ohwada C; Murata M; Satake A; Yoshida C; Nakase K; Mori Y; Tanimoto M
Acta Med Okayama; 2016 Oct; 70(5):429-433. PubMed ID: 27777442
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.
Heiler S; Lötscher J; Kreuzaler M; Rolink J; Rolink A
Front Immunol; 2018; 9():656. PubMed ID: 29670626
[TBL] [Abstract][Full Text] [Related]
25. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease.
Oarbeascoa G; Lozano ML; Guerra LM; Amunarriz C; Saavedra CA; Garcia-Gala JM; Viejo A; Revilla N; Acosta Fleitas C; Arroyo JL; Martinez Revuelta E; Galego A; Hernandez-Maraver D; Kwon M; Diez-Martin JL; Pascual C;
Biol Blood Marrow Transplant; 2020 Apr; 26(4):651-658. PubMed ID: 31917270
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 and regulatory T cells in graft-versus-host disease.
Koreth J; Matsuoka K; Kim HT; McDonough SM; Bindra B; Alyea EP; Armand P; Cutler C; Ho VT; Treister NS; Bienfang DC; Prasad S; Tzachanis D; Joyce RM; Avigan DE; Antin JH; Ritz J; Soiffer RJ
N Engl J Med; 2011 Dec; 365(22):2055-66. PubMed ID: 22129252
[TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
28. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.
Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF
Front Immunol; 2019; 10():334. PubMed ID: 30894856
[TBL] [Abstract][Full Text] [Related]
29. Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles.
Bertani G; Santoleri L; Ferri U; Marenco P; Grillo G; Zucchetti E; Forno B; Lando G; Scarpati B; Cairoli R; Rossini S; Cesana C
Transfusion; 2016 Feb; 56(2):505-10. PubMed ID: 26453579
[TBL] [Abstract][Full Text] [Related]
30. A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.
Salhotra A; Falk L; Park G; Sandhu K; Ali H; Modi B; Hui S; Nakamura R
Expert Rev Clin Immunol; 2024 Feb; 20(2):169-184. PubMed ID: 37921226
[TBL] [Abstract][Full Text] [Related]
31. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.
Kim SJ; Lee JW; Jung CW; Min CK; Cho B; Shin HJ; Chung JS; Kim H; Lee WS; Joo YD; Yang DH; Kook H; Kang HJ; Ahn HS; Yoon SS; Sohn SK; Min YH; Min WS; Park HS; Won JH
Haematologica; 2010 Nov; 95(11):1935-42. PubMed ID: 20663943
[TBL] [Abstract][Full Text] [Related]
32. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
[TBL] [Abstract][Full Text] [Related]
33. Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH).
Parra Salinas I; Bermudez A; López Corral L; Lopez Godino O; Móles-Poveda P; Martín G; Costilla Barriga L; Ferrá Coll C; Márquez-Malaver F; Ortí G; Zudaire Ripa MT; Rifon J; Martinez C;
Clin Transplant; 2021 May; 35(5):e14255. PubMed ID: 33595866
[TBL] [Abstract][Full Text] [Related]
34. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
Matsuoka K; Koreth J; Kim HT; Bascug G; McDonough S; Kawano Y; Murase K; Cutler C; Ho VT; Alyea EP; Armand P; Blazar BR; Antin JH; Soiffer RJ; Ritz J
Sci Transl Med; 2013 Apr; 5(179):179ra43. PubMed ID: 23552371
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
Redondo S; Esquirol A; Novelli S; Caballero AC; Garrido A; Oñate G; López J; Moreno C; Saavedra SD; Granell M; Briones J; Sierra J; Martino R; García-Cadenas I
Transplant Cell Ther; 2022 Jan; 28(1):43.e1-43.e5. PubMed ID: 34757054
[TBL] [Abstract][Full Text] [Related]
36. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
[TBL] [Abstract][Full Text] [Related]
37. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
38. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.
Wolff D; Fatobene G; Rocha V; Kröger N; Flowers ME
Bone Marrow Transplant; 2021 Sep; 56(9):2079-2087. PubMed ID: 34218265
[TBL] [Abstract][Full Text] [Related]
39. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Waller EK; Miklos D; Cutler C; Arora M; Jagasia MH; Pusic I; Flowers MED; Logan AC; Nakamura R; Chang S; Clow F; Lal ID; Styles L; Jaglowski S
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2002-2007. PubMed ID: 31260802
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
